
Lysosomal Disorders
Latest News
Latest Videos

More News

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 27, 2023.

The therapy has been well-tolerated in the first 3 participants which also showed GCase expression in the plasma.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 20, 2023.

MSEL 5-mean domain, receptive language, and expressive language scores were significantly improved from baseline in treated participants.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Intellia Therapeutics plans to initiate the phase 3 trial of NTLA-2001 by the end of 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A NEWDIGS analysis compared clinical trial success rates from 1988 to 2020.

Review top news and interview highlights from the week ending October 6, 2023.

The updated data are from the first 2 patients treated in the phase 1/2 GALILEO-1 trial of FLT201.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The therapy has a PDUFA date of March 31, 2024.

Review top news and interview highlights from the week ending September 29, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Abeona has submitted a BLA for its EB-101 cell therapy.

Review top news and interview highlights from the week ending September 22, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The PDUFA data has been set for March 18, 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending September 8, 2023.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The data come from 30 patients treated across 2 clinical trials and 9 patients treated in expanded access frameworks who had follow-up times ranging from 0.64 years to 12.19 years.

Phase 1/2 trials have been cleared in Germany and dosed first patients in the US.